Skip to main content
Fig. 2 | SpringerPlus

Fig. 2

From: Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria

Fig. 2

Cost-effectiveness frontier for Austrian test-treatment strategy T1 (base case) and T2 (sensitivity analysis). Sensitivity analysis: risk group AO intermediate/ODX low receive no chemotherapy whereas in the base case 13.73 % would receive chemotherapy, treatment for other risk groups as in base case); ICER – Incremental Cost-Effectiveness Ratios for the not dominated strategies that are on the frontier (ICER = additional costs/additional QALYs for the next most expensive strategy)

Back to article page